[go: up one dir, main page]

WO2007117272A3 - Methods for treatment of hemorrhagic shock and related disorders - Google Patents

Methods for treatment of hemorrhagic shock and related disorders Download PDF

Info

Publication number
WO2007117272A3
WO2007117272A3 PCT/US2006/038164 US2006038164W WO2007117272A3 WO 2007117272 A3 WO2007117272 A3 WO 2007117272A3 US 2006038164 W US2006038164 W US 2006038164W WO 2007117272 A3 WO2007117272 A3 WO 2007117272A3
Authority
WO
WIPO (PCT)
Prior art keywords
hemorrhagic shock
treatment
methods
related disorders
cardiopulmonary
Prior art date
Application number
PCT/US2006/038164
Other languages
French (fr)
Other versions
WO2007117272A9 (en
WO2007117272A2 (en
Inventor
Elena V Koustova
Original Assignee
Jackson H M Found Military Med
Elena V Koustova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jackson H M Found Military Med, Elena V Koustova filed Critical Jackson H M Found Military Med
Priority to EP06850512A priority Critical patent/EP1940379A4/en
Publication of WO2007117272A2 publication Critical patent/WO2007117272A2/en
Publication of WO2007117272A9 publication Critical patent/WO2007117272A9/en
Publication of WO2007117272A3 publication Critical patent/WO2007117272A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of certain agents for the treatment of hemorrhagic shock and surgical procedures involving a cardiopulmonary by-pass machine. The present invention also comprises methods of preventing, treating, administering and formulating agents that prevent and/or alleviate cellular and tissue damage associated with hemorrhagic shock and surgical procedures involving a cardiopulmonary by-pass machine.
PCT/US2006/038164 2005-09-30 2006-10-02 Methods for treatment of hemorrhagic shock and related disorders WO2007117272A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06850512A EP1940379A4 (en) 2005-09-30 2006-10-02 METHODS OF TREATING A HEMORRHAGIC SHOCK AND RELATED DISORDERS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72197905P 2005-09-30 2005-09-30
US60/721,979 2005-09-30

Publications (3)

Publication Number Publication Date
WO2007117272A2 WO2007117272A2 (en) 2007-10-18
WO2007117272A9 WO2007117272A9 (en) 2007-12-06
WO2007117272A3 true WO2007117272A3 (en) 2008-07-31

Family

ID=38581510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/038164 WO2007117272A2 (en) 2005-09-30 2006-10-02 Methods for treatment of hemorrhagic shock and related disorders

Country Status (2)

Country Link
EP (1) EP1940379A4 (en)
WO (1) WO2007117272A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009055933A1 (en) * 2007-11-02 2009-05-07 Prometic Biosciences Inc. Medium-chain length fatty acids and glycerides as nephroprotection agents
US9435813B2 (en) * 2010-05-11 2016-09-06 The General Hospital Corporation Biomarkers of hemorrhagic shock
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070188A2 (en) * 2002-02-15 2003-08-28 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632078C (en) * 2002-03-04 2012-08-14 Sloan-Kettering Institute For Cancer Research Methods of inducing terminal differentiation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070188A2 (en) * 2002-02-15 2003-08-28 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1940379A4 *

Also Published As

Publication number Publication date
WO2007117272A9 (en) 2007-12-06
WO2007117272A2 (en) 2007-10-18
EP1940379A2 (en) 2008-07-09
EP1940379A4 (en) 2009-05-13

Similar Documents

Publication Publication Date Title
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
GB2442915B (en) Perylenequinone derivatives and uses thereof
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
SG170044A1 (en) Ocular allergy treatments
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
PT2383271E (en) Aminoquinolones as gsk-3 inhibitors
WO2007112014A3 (en) New therapeutic combinations for the treatment of depression
WO2006086693A3 (en) Medical devices
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2007023072A3 (en) Use of ambroxol for the treatment of rhinovirus infections
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
SI1610787T1 (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from tiotropium salts for the treatment of respiratory diseases
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
WO2007130501A3 (en) Combination therapy for treatment of cancer
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders
WO2009047505A3 (en) Dexanabinol with inhibitors of braf or mek for the treatment of melanoma
WO2007095611A3 (en) Use of benzo-fused heteroaryl sulfamide derivatives for the treatment of migraine
MX2021011289A (en) Compositions comprising pkm2 modulators and methods of treatment using the same.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06850512

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2006850512

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE